Randall, there are risks and always will be risks in investing in any emerging company. Obviously up to each individual to decide what level of risk they are comfortable with relative to the potential upside.
If you are not comfortable with the risk, sell your shares and move on - simple.
your comments around the trial, sound like you believe any company could just go and get NIHR funding, with this calibre of respiratory experts. Be worth seeking out some opinions from medical/clinical people around the structure of this trial, and why it is valuable or otherwise.
RSH Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
